The phosphoaminothiol WR1065, the active metabolite of the pro-drug amifostine (WR2721), protects cultured cells and tissues against cytotoxic exposure to radiation or chemotherapeutic agents. We show here that WR1065 and the pro-drug WR2721 activate the p53 tumor suppressor protein and induce the expression of the cyclin-dependent kinase inhibitor p21
Introduction
Over the past few years, amifostine has attracted considerable interest because of its unique properties as a radio and/or chemoprotective agent. Amifostine (s-2[3-aminopropylamino]-ethyl phosphothioic acid, WR2721, Ethyol 1 ) is a pro-drug converted by alkaline phosphatase to its active, dephosphorylated form: WR1065, which can penetrate the cell membrane by both passive and active diusion mechanisms (Yuhas, 1980; Calabro-Jones et al., 1988) . In vitro as well as in intact cells, WR1065 is a potent scavenger of reactive oxygen species and there is convincing evidence that it eciently reduces the extent of DNA-damage caused by free radicals Milligan et al., 1997) . In vivo studies, in mouse and humans, have shown that amifostine accumulated more rapidly in various normal tissues than in tumors (Yuhas, 1980) . This observation has led to the concept that amifostine could be used clinically to limit the side-eects of radio and chemotherapy on normal tissues, while not aecting the therapeutic ecacy on tumors (Capizzi, 1996; Treskes et al., 1992 Treskes et al., , 1994 . The drug is now clinically used to reduce the cumulative renal toxicity associated with administration of platinum drugs in patients treated for ovarian cancers (Schiller et al., 1996) . In cultured cells, amifostine has been reported to exert a wide range of cytoprotective and antimutagenic activities (Clark et al., 1996; Grdina et al., 1985; Smoluk et al., 1998) . Recent evidence also indicates that amifostine stimulates the formation of multi-potent and erythroid bone marrow progenitors and may thus act as a hematopoietic stimulant (List et al., 1998) .
Several experimental and pre-clinical results however suggest that amifostine may also act through more speci®c mechanisms than broad-range, free radical scavenging. Indeed, WR1065, a form of the drug which penetrates equally into cultured cancer and noncancer cells, has been found to have a preferential radioprotective eect on human diploid ®broblasts, as compared to the ®brosarcoma cell line HT-1080 (Zhang et al., 1992) . Thus, the eects of amifostine and its active metabolite may not be restricted to noncancer cells and tissues. In nude mice carrying xenografts of human ovarian cancer cells, amifostine has been reported to potentiate tumor growth inhibition by a standard dose of platinum drugs (Korst et al., 1997 (Korst et al., , 1998 Treskes et al., 1994) . Moreover, WR1065 has been shown to delay cell-cycle progression in cultured cells (Grdina et al., 1994; Grdina and Sigdestad, 1992) , to aect the phosphorylation of topoisomerase IIa Grdina et al., 1994) , and to aect the expression of two genes associated with cell proliferation, c-myc and thymidine kinase (Liu et al., 1997; Woloschak et al., 1995) .
The tumor suppressor protein p53 is a transcription factor which is activated in response to a wide range of stress signals, including hypoxia and DNA-damaging agents (Graeber et al., 1994; Kastan et al., 1991; . The gene encoding p53 is frequently mutated in most common forms of human cancers (Greenblatt et al., 1994) . Target genes transactivated by p53 include regulators of cell cycle progression in G1 (such as the cyclin-dependent kinase inhibitor p21
waf-1 (Bissonnette and Hunting, 1998) ) and G2/M (such as the signal transduction protein 14-3-3s), pro-apoptotic genes (such as bax-1, killer/DR5 and CD95/APO-1/fas) and Oncogene (2000) 19, 1206 ± 1214 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc several genes involved in the control of intracellular redox metabolism (Polyak et al., 1997) . The p53 protein also regulates DNA replication, transcription and repair through molecular mechanisms which involve direct complex formation with several cellular proteins. Overall, these eects allow p53 to play a crucial role as an integrator of multiple cellular responses to stress in the control of cell proliferation, survival and genetic stability (Hainaut and Hollstein, 2000) .
Our group and others have shown that the p53 protein was intrinsically sensitive to oxidation-reduction in vitro (Rainwater et al., 1995; Hainaut and Milner, 1993) . The protein contains a cysteinedependent zinc-binding structure that is reversibly altered by thiol oxidation (Cho et al., 1994) . In intact cells, several metal-chelators and thiol anti-oxidant are potent modulators of the DNA binding and transcriptional activities of p53 (Verhaegh et al., 1997 (Verhaegh et al., , 1998 .
These observations led us to investigate whether WR1065 could aect the activity of the p53 protein.
We show here that exposure of cultured cells to WR1065, as well as to the pro-drug WR2721, induces accumulation and activation of p53, and that this eect is correlated with induction of p53 target genes and eects on the cell-cycle progression. These data raise the possibility that modulation of p53-dependent pathways may play a role in the protective properties of amifostine.
Results

WR1065 induces nuclear accumulation of p53
As experimental systems to assess the eects of WR1065 on p53, we used immortalized mouse ®broblasts (Balb/c 3T3) and the human breast cancer cell line MCF-7, which expresses high levels of wild type p53. The latter cell line has been extensively used as a model to analyse p53 protein functions (Delmolino et al., 1993; Verhaegh et al., 1997) .
First, MCF-7 and Balb/c 3T3 cells were incubated for 30 min in the presence or absence of increasing concentrations of WR1065 (1 ± 2 mM) prior to addition of hydrogen peroxide at cytotoxic concentrations (H 2 O 2 100 mM). After 14 h, cells were ®xed and immuno-stained with antibodies speci®c for p53. Figure 1a ,b show that addition of WR1065 preserved the viability and the morphology of cells exposed to H 2 O 2 . In both cell lines, WR1065 induced a detectable nuclear accumulation of p53 protein. High levels of nuclear p53 were also observed in cells treated with both H 2 O 2 and WR1065. These data show that WR1065, at cytoprotective concentrations, induces the nuclear accumulation of p53.
WT1065 stimulates p53 DNA-binding activity
We have previously shown that several metal-chelators and redox-active compounds could induce p53 to accumulate in a form which is unable to bind speci®cally to DNA (Verhaegh et al., 1997 (Verhaegh et al., , 1998 . To demonstrate whether the p53 protein detected in Figure  1a ,b accumulates in an active form, we analysed the DNA binding activity of p53 in nuclear extracts of MCF-7 cells exposed to increasing concentrations of WR1065. Figure 2 shows that WR1065, at concentrations between 50 mM and 1 mM, induced a dose-dependent nuclear accumulation of p53, correlated with increased DNA binding activity. This activation was already detectable after 2 h of exposure to 50 mM of WR1065 (Figure 2b) .
Similar results were observed with the phosphorylated pro-drug WR2721, albeit at higher concentrations ( Figure 3) . Furthermore, no induction was detected with two other unrelated transcription factors used as controls, Oct-1 (an ubiquitous, constitutively active transcription factor) and NFk-B (which is induced by a variety of signals including oxidation-reduction, cytokines and DNA-damage, Figure 3b ). Overall, these data suggest that WR1065 and the pro-drug WR2721 do not increase the DNA binding activity of transcrip- tion factors in a non speci®c manner and exert eects that dier between two inducible factors, NFkB and p53.
WR1065 induces a p53-dependent accumulation of p21
waf-1 Figure 4 shows that accumulation of p53 in response to WR1065 was accompanied by increased levels of the CDK inhibitor p21
waf-1 protein, a transcriptional target of p53. This observation, in conjunction with these of the previous paragraph, indicate that WR1065 activates p53 transcriptional activity. In the medium of cultured cells, WR1065 may be degraded into cytotoxic metabolites (including H 2 O 2 , acrolein and cysteamine) by Cu-dependent amine oxidases, a reaction that can be inhibited by aminoguanidine (AG) (Meier and Issels, 1995) . However, Figure 4 shows that AG, used at a concentration which inhibits WR1065 catabolism (4 mM), did not block the accumulation of p53 and p21
waf-1 in the nucleus. These results suggest that the induction of p53 and p21
waf-1 by WR1065 is not a secondary eect due to a form of stress induced by toxic compounds generated by the extra-cellular catabolism of WR1065.
Time-course experiments performed with WR1065 at 1 mM in the presence of AG 4 mM ( Figure 5 ) revealed that induction of p53 was rapid (detected after 2 h), with a maximum at 12 ± 24 h and a decrease after longer exposures (not shown). This induction was followed by increased expression of p21 waf-1 ( Figure 5 ). The delay (3 h) between the onset of p53 activation and p21
waf-1 accumulation is consistent with a transcriptional activation of the p21 waf-1 gene by p53. Similar eects were seen on mdm-2, another transcriptional target of p53 (data not shown).
To determine whether this induction of p21 waf-1 was strictly dependent upon p53, we used two modi®ed MCF-7 cell lines, MDD2 and MN1. MDD2 cells are derived from MCF-7 by stable transfection of a segment of the p53 cDNA corresponding to the oligomerization domain, inserted in a Neo gene expressing vector. MN1 is the parental MCF-7 strain, transfected with the Neo vector. Expression of the DD2 peptide prevents oligomerization of full-length p53 and thus blocks its ability to act as a tetrameric transcription factor (Bacus et al., 1996; Shaulian et al., 1992) . Figure 6 shows that exposure to WR1065 (1 mM) in the presence of AG (4 mM) induced p53 and p21
waf-1 accumulation in MN1 cells, but not in MDD2 cells. In this latter cell line, the basal levels of p53 were much higher than in MN1, consistent with accumula- Figure 2 Exposure to WR1065, activates p53 protein in MCF-7 cells. (a) MCF-7 cells were exposed for 2 h to WR1065 at the indicated concentrations. p53 protein was detected by Western blotting with the antibody DO-7. (b) The DNA-binding activity of p53 was analysed by Electro-Mobility-Shift-Assay (EMSA) using a p53 consensus binding oligonucleotide labeled with 32 P, as described in Materials and methods. Only the band corresponding to speci®c p53-DNA complexes is shown. In both a and b, equal amounts of protein from nuclear extracts were loaded (20 mg for Western blot, 10 mg for EMSA) Figure 3 The pro-drug WR2721 has similar speci®c eects on p53 activity. MCF-7 cells were exposed for 2 h to WR2721 at the indicated concentrations and nuclear protein extracts were used for a, detection of p53 by Western blot using DO-7 antibody, b, analysis of DNA-binding activity of p53, Oct-1 and NFkB using corresponding speci®c consensus oligonucleotides labeled with 32 P. Only the portion of the autoradiograms containing the protein-DNA complexes is shown, *non speci®c complex which does not correspond to NFkB DNA-binding activity tion of transcriptionally inactive p53 in complex with the DD2 peptide (Bacus et al., 1996) . Levels of p21 waf-1 were lower in MDD2 than in MN1, indicating that p53 participates in the control of basal p21
waf-1 expression in MN1 and MCF-7 cells. These results clearly demonstrate that induction of p21 waf-1 by WR1065, in an MCF-7 background, is p53-dependent.
Taken together, these results indicate that WR1065 induces p53 to accumulate in a form which binds to speci®c DNA and activates the transcription of p53 target genes.
Spermidine does not induce p53
WR1065 and its oxidized dissul®te linked WR33278 show chemical structures similar to those of naturally occurring polyamines such as spermidine (Wyatt et al., 1989; Mitchell et al., 1998) . To determine whether spermidine may also activate p53, we treated MCF-7 cells with increasing concentrations of either WR1065 or spermidine. Figure 7 shows that WR1065 (1, 2 and 4 mM) induced nuclear accumulation of p53 and p21 waf-1 , whereas spermidine at the same concentrations had no eect. Similar results were obtained in 3T3 cells (not shown). These experiments suggest that p53 induction by WR1065 is not exclusively due to the polyamine-like structure of this compound.
Effects of WR1065 on cell cycle
We next examined whether the induction of p53 and of p21 waf-1 by WR1065 was correlated with modulation of cell cycle. Figure 8 (upper panel) shows that WR1065 at 1 mM induced cells to accumulate in the G1 phase of the cell cycle (from 53% in control to 68% in WR1065-treated cells: +28.3%), with a reduction of cells in S phase (from 24% in control to 15% in WR1065-treated cells: 737.5%). This eect on cell cycle progression is consistent with induction of p53 and subsequent accumulation of the CDKI p21 waf-1 . At higher concentrations of WR1065 (2 and 4 mM), cells arrested at both G1 and G2 phases of the cell cycle, as shown by accumulation in G2 and by low levels of cells in S phase. Moreover, WR1065 induced a detectable increase in the sub-G1 fraction of the cell-cycle pro®le. This fraction corresponds to dying or dead cells, in keeping with the observation that WR1065 at concentrations higher than 1 mM has toxic eects in these cultured cells, which can not be inhibited by AG (data not shown).
The role of p53 in the cell-cycle eects of WR1065 was further analysed by comparing MN1 and MDD2 cells (Figure 9 ). In MN1 cells treated with WR1065 in the presence of AG 4 mM, a delay at the G1/S transition was detected by a modest but reproducible decrease of cells in S phase (729.7%+3.14) and by an increase of the number of cells in both G1 and G2/M (+11.9%+1.7 and +28.4%+14.9 respectively). In contrast, WR1065 had no signi®cant eects on cell cycle distribution in MDD2 cells ( Figure 9 and Table  1 ). The dierence in S phase between MN1 and MDD2 cells was statistically signi®cant (Figure 9 , P50.03 using a 2-tailed t-test, n=4). These results show that waf-1 by WR1065 in presence of the Cu-dependent amine-oxidase inhibitor, aminoguanidine. MCF-7 cells were treated for 12 h with or without 4 mM of AG added 10 min before 1 mM of WR1065. The levels of expression of p53 and p21
waf-1 were analysed by Western blot using respectively DO-7 and C-19 antibodies. p53 and p21
waf-1 are indicated Figure 5 Time-course of the induction of p53 and p21
Waf-1 by WR1065. MCF-7 cells were exposed to aminoguanidine 4 mM 10 min prior to addition of WR1065 at 1 mM and then incubated at 378C for the indicated periods of time. p53 and p21
waf-1 proteins were detected by Western blotting. The blotting membrane was cut into two parts at the level of the 30 kDa molecular weight marker. The upper part was used for p53 detection as described in Figure 2 . The lower part was probed for detection of p21 waf-1 with C19 antibody Figure 6 p21 Waf-1 induction by WR1065 is dependent on p53 activation. MN1 and MDD2 cells, treated with AG 4 mM were exposed, or not, to WR1065 at 1 mM for 14 h as indicated. p53 and p21
waf-1 proteins levels were then detected by Western blotting. The blotting membrane was cut into two parts at the level of the 30 kDa molecular weight marker. The upper part was used for p53 detection as described in Figure 2 . The lower part was probed for detection of p21
waf-1 with C-19 antibody. This lower part was exposed twice, ®rst for 5 s (upper panel), then for 3 min (lower panel), in order to detect the presence of p21
waf-1 in MDD2 cells WR1065, but not spermidine, aect cell cycle progression in a manner which is consistent with the activation of a p53-p21
waf-1 dependent pathway.
WR1065 modifies the induction of p53 in cells exposed g-irradiation WR1065 is thought to exert its radioprotective action by scavenging damaging reactive oxygen species generated by irradiation. Therefore, it should be expected that WR1065 may reduce or inhibit the induction of p53 in cells exposed to g-rays. Figure 10 shows that in the absence of WR1065, the accumulation of p53 induced by irradiation (15 Gy) in MCF-7 cells was rapid (maximum after 3 h) and transient (return to basal levels after 6 h). In cells exposed to WR1065, p53 accumulation was detected after 3 h but levels of p53 remained high after 6 h. When cells were exposed to both g-rays and WR1065, the same response as with WR1065 alone was observed. These results show that, in MCF-7 cells, the induction of p53 by irradiation is modi®ed by the addition of WR1065, and are consistent with a dual eect of the radioprotector. First WR1065 may prevent the formation of DNA-damage by free radicals and therefore inhibit the resulting p53 induction by irradiation. Second, WR1065 may activate p53 by a pathway which is distinct and independent of that elicited by irradiation. The net result of these two eects would be that MCF-7 cells exposed to g-rays and WR1065 are protected against DNA-damage promoted by irradiation, but accumulate active wild type p53 to high levels.
Discussion
The results presented here show that WR1065, the active metabolite of the radio and chemoprotective drug amifostine (WR2721), is a potent activator of p53 in cell lines expressing wild type p53, including MCF-7 cells (human breast cancer), and Balb/c 3T3 (murine ®broblasts). Similar results were also observed in A549 (human lung adenocarcinoma cells expressing wild type p53), and in TE-1 cells (human esophageal squamous cell carcinoma expressing a temperature sensitive mutant p53, D Maurici, S North and P Hainaut, data not shown). Activation of p53 is detected at concentrations of WR1065 (50 mM to 2 mM) which are lower or expression. MCF-7 cells were treated for 12 h with increasing concentrations of either WR1065 or spermidine (0 ± 4 mM) as indicated. P53 and p21 waf-1 expression levels were analysed by Western blot as in Figure 5 . P53 and p21
waf-1 are indicated. Equal amount (15 mg) of protein from nuclear extracts were loaded on each lane Figure 8 Eects of WR1065 on cell cycle distribution. Sub-con¯uent MCF-7 cells were exposed for 12 h to either WR1065 (upper panels) or spermidine (lower panels) at the indicated concentrations (1 ± 4 mM) and the cell cycle distribution was analysed by¯ow cytometry after labeling with Propidium iodide, using a FACSCalibur and the CellQuest software (Becton Dickinson). Control untreated cells are presented on the left. Percentages of cells in each phase of the cell cycle of this experiment are shown in Table 1 Activation of p53 by amifostine S North et al equal to the concentration required to protect MCF-7 or 3T3 cells against the cytotoxicity of hydrogen peroxide at 100 mM. These results indicate that WR1065 activates p53 at concentrations compatible with protective properties in vitro. Moreover, these concentrations are compatible with those found in most normal tissues of rat or mice 10 ± 15 min after injection of a single dose of WR2721 at 200 mg/kg (Yuhas, 1980) . It is interesting to note that this dose is commonly used in radio/or chemoprotection experiments in rodents (Treskes et al., 1992 (Treskes et al., , 1994 . Our data also suggest that the induction of p53 by WR1065 is an intrinsic property of the drug. This induction does not result from generalized oxidative stress, that would have also induced NFk-B (Piette et al., 1997) , nor from the formation of toxic metabolites Figure 9 The eect of WR1065 on cell-cycle distribution is dependent upon p53. Sub-con¯uent MN1 (a) and MDD2 (b) cells were treated with AG 4 mM and then exposed or not for 14 h to WR1065 at the indicated concentrations (0.5 and 1 mM). The cell cycle distribution was analysed by¯ow cytometry after labeling with Propidium iodide, using a FACSCalibur and the CellQuest software In a recent report, Martinez et al. (1997) have shown that WR1065 (1 mM) could completely block the nuclear translocation of p53 following irradiation or H 2 O 2 treatment in the rat ®broblast cell line A1-5. In contrast with this observation, we report here that WR1065 induced p53 to accumulate into the nucleus and we did not detect any substantial accumulation of p53 in the cytoplasm. This dierence may be due to the fact that A1-5 cells contain a mutant form of p53 which is constitutively cytoplasmic but enters the nucleus after irradiation. In the two cell lines used in the present report, the p53 protein is wild type and is constitutively nuclear, a situation which corresponds to the sub-cellular distribution of the p53 protein in normal cells.
Induction of p53 by WR1065 is followed by increased expression of p21 waf-1 (see Figure 3 ) and mdm2 (data not shown), two transcriptional targets of p53 in a number of cell lines. p21
waf-1 has been shown to be regulated by several p53-independent pathways (Loignon et al., 1997) . However, experiments with the p53 disabled cell line MDD2 clearly demonstrate that activation of p21 waf-1 by WR1065 is p53-dependent. Exposure to WR1065 induced MN1 cells to accumulate in G1, with a reduction of 23.9%+4.4 (at 0.5 mM WR1065) and 29.8%+3.1 (at 1 mM WR1065) of cells in S phase whereas no signi®cant eects were seen in MDD2 at these concentrations. These data are consistent with a role of p53-induced p21
waf-1 expression in G1/S cell cycle regulation by WR1065. However, WR1065 at higher concentration also aected the cell cycle distribution in a p53-independent manner. In all cell lines tested (MCF-7, MN1, MDD2, A549 and mouse ®broblasts), WR1065 at 2 ± 4 mM induced accumulation of cells in G2/M and increased cytotoxicity. Accumulation in late S or early G2/M has been reported previously and has been interpreted as a possible consequence of inhibition of topoisomerase IIa . Cytotoxicity may re¯ect the formation of toxic catabolites of WR1065 in the culture medium (which is only partially prevented by AG with concentrations of WR1065 higher than 1 mM), or toxic eects resulting from the perturbation of intracellular polyamine metabolism. The precise mechanism of activation of p53 by WR1065 is not known. One possible mechanism may involve the perturbation of the intracellular polyamine metabolism. Polyamines play multiple roles in the control of cell growth, in promotion of interaction of DNA-binding proteins to their target DNA, and a speci®c role in activation of Casein Kinase II (CK2), an enzyme that phosphorylates p53 (Leroy et al., 1997; Meek, 1998) . In a recent study, Kramer et al. (1999) have reported that several synthetic polyamines produce a distinct G1 and G2/M cell-cycle arrest in a human melanoma cell line expressing wild type p53. Treatment with a spermidine analog, N-N-diethylnorspermidine, caused an increase in p53 and a concomitant increase in p21 waf-1 . Based on these observations, these authors suggested that depletion of the pool of natural polyamines induced by the analog may activate p53, thereby de®ning a role for polyamines in the regulation of upstream eectors involved in the p53 response. It is possible that this mechanism may account for the eects of WR1065 on p53. However, it is important to note that another polyamine, spermidine, did not induce any detectable change in the level or activity of p53 in MCF-7 cells. Spermidine is a natural polyamine with high structural analogy with WR1065 and WR3328, the di-thiol-linked intracellular metabolite of WR1065. It is not known whether spermidine induces similar eects on intracellular polyamine metabolism as WR1065 or as other synthetic polyamine analogs. Overall, our results suggest that induction of p53 by WR1065 is not exclusively due to the structural similarity of this compound to natural polyamines and that other biochemical properties of this drug may play an important role.
WR1065 is a potent free-radical scavenger. It has been shown that p53 protein is intrinsically sensitive to oxidation-reduction (see introduction) and its activity can be modulated by various anti-oxidants. Thus a direct, anti-oxidant role of WR1065 on p53 regulation could be involved. However, in contrast with amifostine, other anti-oxidant tested so far in our laboratory (including N-acetyl-L-cysteine, dihydrolipoic acid and pyrrolidine dithiocarbamate) all down-regulated p53 protein activity to variable extent (Verhaegh et al. (1997), Furukawa and Hainaut, unpublished data) . Another hypothesis is that WR1065 may induce some form of DNA-damage that could, in turn, activate p53. A possible cause of DNA-damage may be the intracellular production of reactive oxygen species generated by redox-dependent reaction involving the thiol-group or by enhanced polyamine catabolism. This hypothesis is Percentage of cells in G1, S and G2/M phases of the cell cycle corresponding to MN1 and MDD2 cells treated with WR1065 (0.5 and 1 mM), from one typical experiment described in Figure 9 . The percentage of variation related to the control untreated cells are indicated in brackets (+ or 7). The proportions of cells in each phase were obtained using automatical analysis by ModFit LT 2.0 software Figure 10 WR1065 modulates the induction of p53 after girradiation. MCF-7 cells were treated or not for 2 h with WR1065 1 mM and AG 4 mM and then irradiated or not at 15 Gy. The levels of expression of p53 were analysed by Western blot (DO-7 antibody) 3 and 6 h post-irradiation however unlikely, since the eect of WR1065 on p53 is clearly dierent from that of agents inducing DNA strand breaks through free radical production. In particular, WR1065 induced a progressive and long lasting accumulation of p53, whereas the eects of H 2 O 2 or g-irradiation were rapid and transient. Furthermore, the aminothiol WR1065 did not activate NFk-B, a transcription factor rapidly stimulated by oxidative stress (Piette et al., 1997) . We therefore favor the hypothesis that WR1065 induces p53 by a pathway which does not require the formation of DNA-damage. There is evidence that p53 is also activated by non genotoxic stimuli including hypoxia (Graeber et al., 1994; An et al., 1998) , agents that deplete the ribonucleotide pool (Linke et al., 1996) or cytokines (Donato and Perez, 1998) . Other mechanisms may include destabilization of chromatin structures by WR1065 which has been described by Vaughan et al. (1989) .
In conclusion, our results indicate that activation of p53 by WR1065 may alter cell cycle progression in G1 or decrease entry in S phase. As p53 plays a central role in the coordination of cellular response to cytotoxic injury (see introduction), it is tempting to speculate that activation of p53 may play a role, among other eectors, in the pathways by which WR1065 acts as a cytoprotector that distinguishes between normal and cancer cells in vivo. Indeed, there is also evidence that WR1065 and WR2721 modulate the activity of other regulators of cell proliferation such as c-myc (Liu et al., 1997) and topoisomerase IIa (Woloschak et al., 1995; Murley et al., 1997) . Further studies are needed to determine the part played by activation of p53 in the cytoprotective properties of WR1065 and of amifostine.
Materials and methods
Cell culture and treatments
The human breast carcinoma cell line MCF-7 cells and mouse 3T3 ®broblasts were routinely cultured in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal calf serum (PAA, Linz, Austria), 2 mM L-glutamine and antibiotics, at 378C under an atmosphere of 10% CO 2 . MN1 and MDD2 cells (Bacus et al., 1996; Shaulian et al., 1992) , derived from MCF-7 cells, were cultured in DMEM supplemented with 5% fetal calf serum, 2 mM L-glutamine, antibiotics and Geneticine 0.4 mg/ml (Life Technologies), at 378C under an atmosphere of 10% CO 2 . Cells were treated with dierent drugs at 50 to 65% con¯uency. WR2721 and the free thiol metabolite WR1065 were provided by US Bioscience. Spermidine (Sigma, USA), WR2721 and WR1065 were dissolved in phosphate-buered saline (PBS) and¯ushed with Argon to prevent oxidation. Aminoguanidine (Sigma) was dissolved in supplemented cell culture medium and added to cells 10 min before WR1065.
Nuclear protein extraction
Control and treated cells were washed twice with ice-cold phosphate-buered saline (PBS) and collected by scraping. Nuclear extracts were prepared as described in Verhaegh et al. (1997) . Brie¯y, cells were lysed for 15 min on ice in 100 ml (per million cells) extraction buer-A (20 mM HEPES pH 7.6, 20% glycerol, 10 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 1 mM DTT, 0.1% NP40), containing protease inhibitors (0.5 mM PMSF, 0.5 mg/ml leupeptine, 2 mg/ml aprotinin and 0.7 mg/ml pepstatin A). Nuclei were collected by centrifugation at 300 g for 4 min, lysed for 30 min on ice in 50 ml (per million cells) extraction buer-B (buer A with 0.5 M, instead of 10 mM NaCl) and then centrifuged for 15 min at 15 000 g and 48C. The supernatant was designated nuclear fraction' and stored at 7808C.
Immunological detection of p53 and p21
waf-1 protein levels
For detection by Western blot, equal amounts of protein from nuclear extracts were mixed with Laemmli sample buer, resolved on a 10% SDS ± polyacrylamide gel, and transferred to PVDV membranes (Millipore). Western blot analysis was performed with an enhanced chemiluminescence detection system (ECL, Amersham, UK) in accordance with the manufacturer's instructions. For human p53 detection, the ®rst antibody used was DO-7 (DAKO, Denmark) at 250 ng/ml; for detection of mouse p53, CM5 antibody (Novocastra, UK) was used. For p21 waf-1 detection, and C-19 antibody (Santa Cruz, USA) was used at a concentration of 200 to 500 ng/ml. Peroxidase conjugated goat anti-mouse or anti-rabbit IgG (Pierce) at a concentration of 250 ng/ml were used as secondary antibodies.
For detection by immunocytochemistry, cells were cultured in chamber slides (Labtek, Becton Dickinson, USA), and treated overnight with WR1065 (1 or 2 mM) with or without H 2 O 2 (100 mM). Cells were then washed in PBS, ®xed in ice cold 1 : 1 (v:v) acetone/methanol, incubated for 1 h in PBS-NP40 0.1% containing 5% BSA at 48C and labeled for 1 h at room temperature with the primary anti-p53 antibody (PAb1801, Oncogene Science, 1 mg/ml for MCF-7 cells; CM5, 1 mg/ml for 3T3 cells). After ®ve washings in PBS-NP40 0.1%, ®xed antibodies were detected with goat antimouse or goat anti-rabbit immunoglobulin G (1/300, Pierce, USA) followed by diaminobenzidine (DAB) staining using a Peroxidase substrate kit DAB (Vector Laboratories Inc., Burlingame, USA).
Electrophoretic gel Mobility-Shift Assay (EMSA)
The double-stranded p53 consensus binding-sequence p53 con (5'-GGACATGCCCGGGCATGTCC-3'), an oligonucleotide containing the Oct-1 binding sequence (underlined; 5'-GACCACCTGGGTAATTTGCATTTCTAAAATA-3') and an oligonucleotide containing the NF-kB binding sequence (5'-GGTTACAAGGGACTTTCCGCTG-3') were synthesized, hybridized and end-labeled with *3000 Ci/mmol g-32 P-ATP (Amersham) as described in Verhaegh et al. (1997) .
Binding assays contained 32 P-labeled double-strand oligonucleotide (0.5 ng), nuclear extract (10 mg), sonicated herringsperm DNA (2 mg; Promega, USA), BSA (5 mg), DTT (4 mM) and were adjusted to a ®nal volume of 30 ml with buer A. For p53 EMSA, all reactions were carried out in the presence of the monoclonal antibody PAb421 (100 ng, Oncogene Science). This antibody stabilizes p53-DNA complexes and is required to detect stable binding of p53 in cellular extracts.
Binding reactions were incubated for 30 min at 208C. A 15-ml aliquot of each reaction was loaded onto a 4% non-denaturing polyacrylamide gel (for p53 and oct-1) and run in TBE buer at 120 V for 2 ± 3 h. For NFk-B-DNA binding assay, the concentration of non-denaturing PAGE was 6%. Gels were then ®xed, dried and exposed to KODAK X-ray ®lms at 7808C for 12 ± 48 h. The speci®city of the binding was extensively controlled by competition experiments using cold oligonucleotides and using mutant DNA consensus sequence (Verhaegh et al., 1997) .
Cell cycle analysis using flow cytometry
Nuclei of treated cells were collected and stained with propidium iodide, using the cycle TEST-PLUS DNA-staining kit, according to the manufacturer's instructions (Becton Dickinson, San Jose, CA, USA). The DNA content of the stained nuclei were measured on a FACSCalibur¯ow cytometer and results were analysed using the CellQuest and ModFit LT2.0 softwares (Becton Dickinson).
